Some people may think that if you just give a whole boat load of engineered T cells, and in particular, those modified with a Chimeric Antigen Receptor (CAR), that responders are “cured.”
While some recipients of engineered T cells can have long-term, durable remissions, others may initially respond, only to subsequently relapse.
Resistance to CAR T cell therapy can and does occur.
In this post, we talked with a leading expert about the latest research on how resistance to cell therapy develops, and the potential strategies to overcome it.
CAR T cell therapy is exciting, but remains an emerging field with multiple ways in which the competitive landscape may be shaped moving forwards.
Subscribers can login to read more.
After last week’s post on therapeutic tumor infiltrating lymphocytes (TILs), we received a bunch of questions from readers.
I don’t have time to answer them all in detail individually (sorry!), but it does provide an opportunity to review the evolving landscape and address some of them within the latest article.
It seems to be a good time to take a broader look at T cell manipulation, especially as it pertains to the application of TILs, chimeric antigen receptors (CAR), and T cell receptors (TCR).
We’ve certainly come along way since the historic lecture in 1991 pictured right (photo: National Institutes of Health), but there’s still some way to go before the full potential of cancer immunotherapy is reached.
To learn more about these sentiments and insights, subscribers can log-in or you can purchase access to BSB Premium Content below…